Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21

In this study, Hussain et al. demonstrate that cancer-associated fibroblasts (CAFs) in high-grade serous ovarian cancer are heterogeneous, that CAF state drives cancer aggressiveness and patient outcomes, and that TCF21 is a master regulator of CAF state.

[1]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[2]  C. Sessa,et al.  Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  T. Chun,et al.  Transcription factor 21 (TCF21) promotes proinflammatory interleukin 6 expression and extracellular matrix remodeling in visceral adipose stem cells , 2018, The Journal of Biological Chemistry.

[4]  A. Vincent-Salomon,et al.  miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers , 2018, Nature Communications.

[5]  Inna Kuperstein,et al.  Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. , 2018, Cancer cell.

[6]  B. Sikic,et al.  Reannotation and Analysis of Clinical and Chemotherapy Outcomes in the Ovarian Data Set From The Cancer Genome Atlas. , 2018, JCO clinical cancer informatics.

[7]  H. Yao,et al.  CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness , 2018, Cell.

[8]  Hans Clevers,et al.  Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer , 2017, The Journal of experimental medicine.

[9]  R. Kalluri.  The biology and function of fibroblasts in cancer , 2016, Nature Reviews Cancer.

[10]  C. Gaggioli,et al.  Fibroblast activation in cancer: when seed fertilizes soil , 2016, Cell and Tissue Research.

[11]  B. Aronow,et al.  Genetic lineage tracing defines myofibroblast origin and function in the injured heart , 2016, Nature Communications.

[12]  Yuli Lin,et al.  FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. , 2016, Cancer research.

[13]  N. Rosenfeld,et al.  Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma , 2016, The journal of pathology. Clinical research.

[14]  B. Monk,et al.  Anti-angiogenic agents in ovarian cancer: past, present, and future. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Stephen T. C. Wong,et al.  Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment , 2016, Biomolecules.

[16]  Zhenfeng Zhang,et al.  Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer , 2015, Scientific Reports.

[17]  K. Yamaguchi,et al.  Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  O. Larsson,et al.  A stringent validation of mouse adipose tissue identity markers. , 2015, American journal of physiology. Endocrinology and metabolism.

[19]  Clint L. Miller,et al.  Coronary Artery Disease Associated Transcription Factor TCF21 Regulates Smooth Muscle Precursor Cells That Contribute to the Fibrous Cap , 2015, PLoS genetics.

[20]  Yulei N. Wang,et al.  Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer , 2015, Clinical Cancer Research.

[21]  Song Liu,et al.  Stromal Expression of Fibroblast Activation Protein Alpha (FAP) Predicts Platinum Resistance and Shorter Recurrence in patients with Epithelial Ovarian Cancer , 2015, Cancer Microenvironment.

[22]  M. Birrer,et al.  Calcium Dependent FAK/CREB/TNNC1 Signaling Mediates the Effect of Stromal MFAP5 on Ovarian Cancer Metastatic Potential , 2014, Nature Communications.

[23]  J. Danska,et al.  Cell Surface Profiling Using High-Throughput Flow Cytometry: A Platform for Biomarker Discovery and Analysis of Cellular Heterogeneity , 2014, PloS one.

[24]  Daniel Öhlund,et al.  Fibroblast heterogeneity in the cancer wound , 2014, The Journal of experimental medicine.

[25]  D. Fearon.  The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance , 2014, Cancer Immunology Research.

[26]  J. Delord,et al.  Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition , 2014, Cancer and Metastasis Reviews.

[27]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[28]  M. Junttila,et al.  Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.

[29]  Hui Liu,et al.  Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. , 2013, The Journal of clinical investigation.

[30]  K. Cibulskis,et al.  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.

[31]  K. Yutzey,et al.  Pod1/Tcf21 is regulated by retinoic acid signaling and inhibits differentiation of epicardium-derived cells into smooth muscle in the developing heart. , 2012, Developmental biology.

[32]  E. Olson,et al.  The bHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors , 2012, Development.

[33]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[34]  Ricardo Garcia,et al.  Biomechanical Remodeling of the Microenvironment by Stromal Caveolin-1 Favors Tumor Invasion and Metastasis , 2011, Cell.

[35]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[36]  B. Neel,et al.  Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells , 2011, Proceedings of the National Academy of Sciences.

[37]  James O. Jones,et al.  Suppression of Antitumor Immunity by Stromal Cells Expressing , 2022 .

[38]  Ross Tubo,et al.  Mesenchymal stem cells within tumour stroma promote breast cancer metastasis , 2007, Nature.

[39]  Robert A. Weinberg,et al.  Heterogeneity of stromal fibroblasts in tumor , 2007 .

[40]  Mark W. Kieran,et al.  Identification of fibroblast heterogeneity in the tumor microenvironment , 2006, Cancer biology & therapy.

[41]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[42]  W. Ansorge,et al.  Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. , 2005, Experimental hematology.

[43]  S. Hwang,et al.  Differential Gene Expression Profiling of Human Umbilical Cord Blood–Derived Mesenchymal Stem Cells by DNA Microarray , 2005, Stem cells.

[44]  Masataka Nakamura,et al.  Basic Helix-Loop-Helix Transcription Factor Epicardin/Capsulin/Pod-1 Suppresses Differentiation by Negative Regulation of Transcription* , 2003, The Journal of Biological Chemistry.

[45]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[46]  P. Ngo,et al.  Collagen gel contraction assay. , 2006, Methods in molecular biology.